

LITERATUR

1. Maggioni AP et al. The real-world evidence of heart failure: findings from 41413 patients of the ARNO database. *Eur J Heart Fail* 2016;18(4):402–410
2. Lesyuk W et al. Cost-of-illness studies in heart failure: a systematic review 2004-2016. *BMC Cardiovasc Disord* 2018;18(1):74
3. Holstiege J et al. Versorgungsatlas 2018, Prävalenz der Herzinsuffizienz – bundesweite Trends, regionale Variationen und häufige Komorbiditäten. Bericht Nr. 18/09; doi:10.20364/VA-18.09
4. Nationale Versorgungsleitlinie: Chronische Herzinsuffizienz. Kurzfassung, 2. Auflage 2017, Version 2 AWMF-Register-Nr.: nvl-006
5. Virani SS et al. Heart Disease and Stroke Statistics – 2020 Update: A Report From the American Heart Association. *Circulation* 2020;141:e139–e596
6. Gheorghide M et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. *Am J Cardiol* 2005;96:11G–17G
7. Cowie MR et al. Improving care for patients with acute heart failure: before, during and after hospitalization. *ESC Heart Fail* 2014;1:110–145
8. Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2016;37(27):2129–2200
9. Greene SJ et al. Risk Profiles in Heart Failure. *Circ Heart Fail* 2020; doi:10.1161/CIRCHEARTFAILURE.120.007132
10. Butler J et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol* 2019;73:935–944
11. Setoguchi S et al. Repeated hospitalizations predict mortality in the community population with heart failure. *Am Heart J* 2007;154:260–266
12. McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;00:1–128; doi:10.1093/eurheartj/ehab368
13. McDonald M et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. *Can J Cardiol* 2021;37:531–546
14. McMurray JJV et al. Angiotensin-Nepriylsin Inhibition versus Enalapril in Heart Failure. *N Engl J Med* 2014;371:993–1004
15. Butler J et al. Ten lessons from the EMPEROR-Reduced trial. *Eur J Heart Fail* 2020;22:1991–1993
16. McMurray JV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med* 2019;381:1995–2008
17. Packer M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med* 2020;383:1413–1424
18. Teerlink JR et al. Cardiac Myosin Activation with Omecamtiv Mercarbil in Systolic Heart Failure. *N Engl J Med* 2021;384:105–116
19. Solomon SD et al. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. *JACC Heart Failure* 2016;4(10):816–822
20. Zile MR et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. *J Am Coll Cardiol* 2016;68:2425–2436
21. Gheorghide M et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. *Heart Fail Rev* 2013;18:123–134
22. Mann DL et al. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier/Saunders; 2015
23. Boerrigter G et al. Modulation of cGMP in heart failure: a new therapeutic paradigm. *Handb Exp Pharmacol* 2009;191:485–506
24. Breitenstein S et al. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. *Handb Exp Pharmacol* 2017;243:225–247
25. Felker G & Mann D. Heart Failure: A Companion to Braunwald’s Heart Disease. Elsevier; 2020

26. Armstrong PW et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. *JACC Heart Fail* 2018;6:96–104
27. Follmann M et al. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. *J Med Chem* 2017;60:5146–5161
28. Armstrong PW et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med* 2020;382:1883–1893
29. McMurray JJV et al. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. *Eur J Heart Fail* 2019;21:1402–1411
30. Butler J et al. Comparing the Benefit of Novel Therapies Across Clinical Trials – Insights from the VICTORIA Trial. *Circulation* 2020;142:717–719
31. Voors AA et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. *Eur J Heart Fail* 2021;23(8):1313–1321
32. Lam CSP et al. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Events: Insights From the VICTORIA-Trial. *JAMA Cardiol* 2021;6(6):706–712
33. Ezekowitz JA. et al., N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. *JACC Heart Fail* 2020; doi:10.1016/j.jchf.2020.08.008